Curasight to present at Kapital Partners Life Science seminar

May 16, 2022

Regulatory

Curasight A/S (TICKER: CURAS) announced today that Chief Executive Officer Ulrich Krasilnikoff and Chief Scientific Officer professor Andreas Kjær will give an update on company strategy and progress in developing new treatment options for cancer diseases, at Kapital Partners Life Science seminar, 18 May 2022.

The presentation will be webcasted live 11:00 - 11:25 (CET), Wednesday 18 May 2022.

For more information – please click here

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Downloads

Kapital Partners Seminar Press Release 16-05-2022

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.